Skip to main content
C
CorpDigest
Search

F. Hoffmann-La Roche AG

Pharmaceuticals and DiagnosticsFounded 1896
Reviewed by Swet Parvadiya
Company data updated: October 2026

Leadership History

Roche: CEO History

3 leaders · 1978 to present

Who is the CEO of Roche?

Thomas Schinecker is the CEO of Roche, in the role since 2023. The first chief executive was Fritz Gerber, from 1978.

Current CEO
Thomas Schinecker (since 2023)
First CEO
Fritz Gerber (1978)
Leaders documented
3
Founded
1896
NameRoleFromToYears in role
Thomas SchineckerChief Executive Officer2023Present3
Severin SchwanChief Executive Officer2008202315
Fritz GerberChairman and Chief Executive Officer1978199820
Who was CEO of Roche before Thomas Schinecker?
Severin Schwan was CEO of Roche from 2008 to 2023, before Thomas Schinecker took over in 2023.

Company Overview

Roche Holding AG is a Swiss healthcare company headquartered in Basel and listed on the SIX Swiss Exchange (ROG non-voting equity securities and RO bearer shares; RHHBY ADRs in the US). It is one of the largest pharmaceutical companies by sales and the largest in vitro diagnostics supplier. Key subsidiaries include Genentech in the US, Chugai Pharmaceutical in Japan and Foundation Medicine. The company is headquartered in Basel, Switzerland.

Roche makes money in two ways. The Pharmaceuticals Division (~$57.2 billion (CHF 47.7 billion) in 2025) sells patented medicines, mostly biologics, in oncology, neuroscience, immunology, ophthalmology and haemophilia; top growth drivers in 2025 were Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo. The Diagnostics Division (~$16.6 billion (CHF 13.8 billion)) places cobas, Elecsys and Ventana instruments in laboratories and earns recurring revenue from the reagents, tests and service contracts needed to run them. Companion diagnostics link the two: a Roche test can identify the patients most likely to benefit from a Roche drug.

Thomas Schinecker

Chief Executive Officer

2023 – Present

3 years (current)

Key Decisions & Impact

Schinecker added obesity and metabolic assets through the Carmot (2023) and 89bio (2025) deals and the Zealand Pharma petrelintide partnership, bought Telavant for immunology, and agreed to acquire PathAI in 2026. He also pruned weaker R&D programs to raise pipeline productivity.

Legacy

Under Schinecker, Roche returned to growth after the COVID testing decline: 2025 sales rose 7% at constant rates to ~$73.8 billion (CHF 61.5 billion) and 12 late-stage studies read out positively that year.

Source →

Severin Schwan

Chief Executive Officer

2008 – 2023

15 years

Key Decisions & Impact

Schwan executed the absolutely massive, highly strategic acquisition of Spark Therapeutics for $4.3 billion, aggressively pivoting the legacy pharmaceutical giant into the bleeding edge of gene therapy.

Legacy

Serving as CEO from 2008 to 2023, he cemented Roche's absolute dominance in global oncology and highly advanced diagnostics before moving to Chairman of the Board.

Source →

Fritz Gerber

Chairman and Chief Executive Officer

1978 – 1998

20 years

Key Decisions & Impact

Gerber became chairman and chief executive in 1978 after the Seveso accident.

Legacy

He bought a majority of Genentech in 1990 and Boehringer Mannheim in 1997. Franz Humer succeeded him as chief executive in 1998.

Source →

Challenges & Strategic Context

Roche faces biosimilar erosion on older biologics, pricing pressure in the United States and Europe, clinical-trial risk in oncology and neuroscience, diagnostics pricing pressure, and the need to replace maturing blockbusters with newer medicines.

Roche CEO and Leadership FAQ

Who is the Chief Executive Officer of Roche today?

Thomas Schinecker has served as Chief Executive Officer of the Roche Group since March 14, 2023, succeeding Severin Schwan.

What was Thomas Schinecker's background before becoming CEO of Roche?

Schinecker, an Austrian-German molecular biologist with a Ph.D. from New York University (NYU), joined Roche in 2003 through its management trainee program. He rose through regional diagnostics roles in Germany, Sweden, and the US before becoming CEO of Roche Diagnostics in 2019.

What was Thomas Schinecker's major achievement as Diagnostics CEO?

Schinecker steered Roche Diagnostics through the COVID-19 pandemic, leading the rapid creation, global manufacturing scaling, and worldwide delivery of millions of molecular PCR and rapid antigen tests, generating record division revenue.

How long did Severin Schwan serve as CEO and what is his current role?

Severin Schwan served as CEO of Roche for 15 years from 2008 to 2023, steering the full acquisition of Genentech, navigating biosimilar patent cliffs, and repurchasing Novartis's stake. In March 2023, Schwan was elected Chairman of the Board of Directors.

Who was Franz Humer and what was his impact on Roche?

Franz Humer served as CEO of Roche from 1998 to 2008 and Chairman until 2014. He orchestrated the historic focus on oncology and biotechnology, successfully defending Roche against a hostile takeover bid by rival Novartis in the early 2000s.

Who heads the Roche Pharmaceuticals Division today?

Teresa Graham was appointed CEO of Roche Pharmaceuticals in March 2023. A longtime Genentech commercial executive who joined in 2005, Graham previously served as Head of Global Product Strategy.

Who leads the Roche Diagnostics Division today?

Matt Sause was appointed CEO of Roche Diagnostics in January 2023. A 20-year Roche veteran, Sause previously served as President and CEO of Roche Diagnostics North America.

How does Roche ensure succession continuity in executive leadership?

Roche prides itself on cultivating long-tenured internal talent. CEOs Severin Schwan, Thomas Schinecker, Teresa Graham, and Matt Sause all spent 15 to 25+ years rising through internal operating ranks before reaching the corporate executive committee.

What major strategic priorities has Thomas Schinecker established since taking over?

Schinecker restructured the R&D pipeline to terminate low-probability phase-1 trials, prioritized high-impact acquisitions in metabolic disease (Carmot GLP-1s) and immunology (Telavant), and accelerated AI-driven drug design partnerships.

Who is the spokesperson for the controlling Hoffmann-Oeri shareholder family?

Dr. Jörg Duschmalé, a fifth-generation descendant of founder Fritz Hoffmann, serves as a member of the Board of Directors and represents the family shareholder pool on corporate governance matters.

How is executive compensation structured at Roche?

Executive compensation emphasizes long-term value creation over short-term quarterly targets, balancing fixed salary with performance bonuses and multi-year stock awards tied to clinical pipeline success, ROIC, and sustainability goals.

What is the relationship between the CEO and the Board of Directors at Roche?

Unlike US corporations where the CEO frequently serves as Chairman, Swiss corporate governance best practices at Roche maintain a distinct separation: Severin Schwan serves as Chairman of the Board, while Thomas Schinecker leads operational executive management.

Related Companies

Novo Nordisk A/SEli Lilly and CompanyNovartis AGBausch Health Companies Inc.

Compare F. Hoffmann-La Roche AG Leadership With Competitors

F. Hoffmann-La Roche AG vs Novo Nordisk A/S Leadership →Overview
F. Hoffmann-La Roche AG vs Eli Lilly and Company Leadership →Overview
F. Hoffmann-La Roche AG vs Novartis AG Leadership →Overview
F. Hoffmann-La Roche AG vs Bausch Health Companies Inc. Leadership →Overview

Related Leadership Timelines

Compare executive leadership tenures and strategic transitions

Competitor

Novo Nordisk A/S

View Leadership Timelines
Competitor

Eli Lilly and Company

View Leadership Timelines
Competitor

Novartis AG

View Leadership Timelines
Competitor

Bausch Health Companies Inc.

View Leadership Timelines
Competitor

Pfizer

View Leadership Timelines
Competitor

Merck

View Leadership Timelines

Explore Roche

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.